Memphasys Limited
Memphasys Limited
Your view on MEM.AX
Overview
What the company does, where it operates, and who runs it.
About Memphasys Limited
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- R. John Aitken
- Headquarters
- 30 Richmond Road, Homebush, NSW, AU
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- R. John Aitken
- Headquarters
- 30 Richmond Road, Homebush, NSW, AU
Memphasys Limited, an Australian enterprise, is dedicated to the development, manufacturing, and distribution of advanced cell and protein separation technologies, alongside associated consumable goods, for the healthcare, veterinary, and biotechnology sectors.
Its leading innovation is Felix, an automated device engineered to swiftly and gently isolate high-quality sperm from raw semen samples, primarily for use in human in vitro fertilization (IVF) procedures.
The company's product portfolio also includes ROSA, a rapid oxidative stress assay; the Samson Device, designed for quick equine pregnancy prediction; SemPort, a system for central laboratory human semen analysis from geographically dispersed donors; and AI-Port, an ambient temperature semen transport solution for animal artificial insemination.
Incorporated in 2006, the company was formerly known as NuSep Holdings Limited until its rebranding to Memphasys Limited in July 2016, and is headquartered in Homebush, Australia.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Memphasys Limited. Starting points for Memphasys Limited: beta 0.47 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Memphasys Limited. Memphasys Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Memphasys Limited. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Memphasys Limited. Memphasys Limited has reported as a listed company since 2007. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | |
|---|---|---|---|---|---|
| ACR.AXAcrux Limited | Healthcare | Biotechnology | — | ||
| BGT.AXBio-Gene Technology Limited | Basic Materials | Agricultural Inputs | — | ||
| BIT.AXBiotron Limited | Healthcare | Biotechnology | — | ||
| CAN.AXCann Group Limited | Healthcare | Drug Manufacturers - Specialty & Generic | — | ||
| CHM.AXChimeric Therapeutics Limited | Healthcare | Biotechnology | — | ||
| HIQ.AXHITIQ Limited | Healthcare | Medical - Healthcare Information Services | — | ||
| IBX.AXImagion Biosystems Limited | Healthcare | Medical - Diagnostics & Research | — | ||
| IVX.AXInvion Limited | Healthcare | Drug Manufacturers - Specialty & Generic | — | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| PRRUFImmutep Limited | Healthcare | OTC | $368.0M | ||
| PRTAProthena Corporation plc | Healthcare | NASDAQ | $428.8M | ||
| PRTCYPureTech Health plc | Healthcare | OTC | — | ||
| PRVCFPreveCeutical Medical Inc. | Healthcare | OTC | $10.1M | ||
| PSYBFPsyBio Therapeutics Corp. | Healthcare | OTC | $1,275 | ||
| PTCHFPureTech Health plc | Healthcare | OTC | $410.4M | ||
| PTCTPTC Therapeutics, Inc. | Healthcare | NASDAQ | $5.0B | ||
| PTGXProtagonist Therapeutics, Inc. | Healthcare | NASDAQ | $8.3B | ||
| PTHSPelthos Therapeutics Inc. | Healthcare | AMEX | $27.9M | ||
| PTIXProtagenic Therapeutics, Inc. | Healthcare | NASDAQ | $470,654 | ||
| PTNPalatin Technologies, Inc. | Healthcare | NASDAQ | $9.2M | ||
| PTX.AXPrescient Therapeutics Limited | Healthcare | ASX | — | ||

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Memphasys Limited.